This Biotech Fund Sold $8 Million, Yet Remains Bullish on Terns
A biotech fund reduced its Terns Pharmaceuticals position by about $8 million last quarter. Despite the sale, the the...
Cash back taxes can be confusing. This guide provides essential insights to help you navigate your tax responsibilities.
22,480 articlesA biotech fund reduced its Terns Pharmaceuticals position by about $8 million last quarter. Despite the sale, the the...
Lucid Group has faced a tough year, with its stock down dramatically. This article breaks down the reasons behind the...
As 2026 unfolds, Resideo's earnings trajectory blends hardware sales with growing recurring revenue. This guide break...
A sharp drop in Planet Labs shares sparked questions about growth, cash burn, and contract momentum. This guide break...
Ford famously pulled back from most sedans years ago. This article examines the strategic pivot, what a sedan comebac...
A downtown Pittsburgh convenience store is at the center of allegations that SNAP benefits were converted to cash and...
Dive into how to read myriad genetics (mygn) 2025 earnings transcripts, spot growth drivers, assess risk, and build a...
When a tech stock dives 84%, it can feel like a lost cause. This guide shows a disciplined way to assess beaten-down ...
Dianthus Therapeutics has surged 320% over the past year, even as a large investor reduced its stake. This article di...
Kratos Defense stock just moved lower after a compelling earnings beat, leaving investors wondering what comes next. ...
Is Elon Musk steering his empire toward semiconductors? This article explores how Musk’s ventures touch chips, what t...
UBS uMINT yield-bearing collateral is now live on Bybit through a three‑party workflow, turning idle cash into produc...